Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Spinocerebellar Ataxia Type 3
Interventions: BIIB132, BIIB132-Matching Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Gainesville, Florida + 7 more

Conditions: NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
Interventions: Cobiprostone, Placebo, Non-steroidal anti-inflammatory drug; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Phoenix, Arizona • Chula Vista, California • Loma Linda, California + 16 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: ziprasidone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 28
States / cities: Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 23 more

Conditions: Anemia
Interventions: Ferric Carboxymaltose, Standard Medical Care (SMC); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
Interventions: LY3873862, CYP450 Drug Cocktail, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: San Francisco, California • Aurora, Colorado • Kansas City, Kansas

Conditions: Spinal Cord Injury, Sleep-disordered Breathing, Spinal Cord Disease, Multiple Sclerosis
Interventions: Best practices PAP + patient Education +ongoing Support and Training, Sleep Education; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: DDD
Interventions: Not listed
Lead sponsor: Interventional Spine, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Los Angeles, California • Saint Augustine, Florida

Conditions: Angelman Syndrome, Prader-Willi Syndrome
Interventions: Newborn Screening Assay; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Not listed
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Kidney Disease, Dialysis, Hyperphosphatemia
Interventions: MCI-196; Drug
Lead sponsor: Tanabe Pharma Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 17
States / cities: Los Angeles, California • Orange, California • Tarzana, California + 14 more

Conditions: ADHD
Interventions: Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg, PRC-063 100 mg; Drug
Lead sponsor: Rhodes Pharmaceuticals, L.P.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 33
States / cities: Los Angeles, California • National City, California • Newport Beach, California + 27 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: SDX-105; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 13
States / cities: Birmingham, Alabama • Palm Springs, California • Vista, California + 10 more

Conditions: Bacteremia
Interventions: Vancomycin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more

Conditions: Insulin-Like Growth Factor-1 Deficiency, Growth Disorders
Interventions: rhIGF-1 (mecasermin) for a period of 86 weeks; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 3 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Face; Atrophy
Interventions: DA-13-007 right with left side Sculptra left side, DA-13-007 left with left side Sculptra right side; Device
Lead sponsor: DermAvance; Industry
Eligibility: 21 Years and older
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Bradenton, Florida • Coral Gables, Florida • Carmel, Indiana + 1 more

Conditions: HIV Infections, Human Immunodeficiency Virus
Interventions: SP01A; Drug
Lead sponsor: Samaritan Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Beverly Hills, California • Fort Lauderdale, Florida • Orlando, Florida + 2 more

Conditions: Stroke, Atrial Fibrillation, Embolism
Interventions: warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 21 Years and older
Enrollment: 21,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 316
States / cities: Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more

Conditions: X-Linked Retinitis Pigmentosa
Interventions: AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen); Biological
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 7
States / cities: Jacksonville, Florida • Miami, Florida • Boston, Massachusetts + 4 more

Conditions: Acne Vulgaris
Interventions: SB204 4%; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 9 Years to 99 Years
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 69
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more

Conditions: Ovarian Cancer, Breast Cancer
Interventions: Questionnaire; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • New York, New York + 1 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Deflazacort; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 4 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Rochester, New York + 1 more

Conditions: Fracture Healing
Interventions: Placebo, Romosozumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 95 Years
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 12
States / cities: Birmingham, Alabama • Pomona, California • Aurora, Colorado + 9 more

Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation, Transplant-ineligible 2nd Line DLBCL
Interventions: zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine; Biological · Drug
Lead sponsor: Miltenyi Biomedicine GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 30
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate Transdermal System; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Irvine, California

Conditions: Arteriovenous Access Grafts or Extra-anatomic and Infra-inguinal Grafts
Interventions: Vascular Sealant System, Gelfoam/Thrombin; Device · Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Timeline: Started 2007
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients

A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).

Treatment of Sleep-disordered Breathing in Patients With SCI

The PerX360º System™ Registry

Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

DA-13-007 Versus Sculptra for the Treatment of Nasolabial Folds Wrinkles

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

P3 Long Term Safety Study of Once Daily SB204 in Acne

Lynne Cohen Consortium Project: Multi-Center Database/Registry

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

Study To Assess FRacTure Healing With SclerosTin Antibody - Hip

DALY II USA/ MB-CART2019.1 for DLBCL

Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD

Vascular Sealant Study